Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.
about
Flibanserin for Treating Hypoactive Sexual Desire DisorderPharmacology of serotonin and female sexual behaviorRetinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-AntagonistBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trialThe Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin.Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients.Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.Advances in pharmacotherapy for treating female sexual dysfunction.Flibanserin: Approval of a controversial drug for a controversial disorderPreclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats.A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review.Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide.Motivated behaviors and levels of 3α,5α-THP in the midbrain are attenuated by knocking down expression of pregnane xenobiotic receptor in the midbrain ventral tegmental area of proestrous rats.Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.An update on the pharmacological management of female sexual dysfunction.Flibanserin: First Global Approval.Flibanserin.Female Sexual Dysfunction: Is It a Treatable Disease?Skills Vs. Pills: Comparative Effectiveness for Low Sexual Desire in Women.Flibanserin - the female Viagra?Flibanserin and its discontents.New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin.Female sexual dysfunction: a focus on flibanserin.Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis.Next-day residual effects of flibanserin on simulated driving performance in premenopausal women.Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder.Brain neuronal activation induced by flibanserin treatment in female rats.Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin.Flibanserin-Stimulated Partner Grooming Reflects Brain Metabolism Changes in Female Marmosets.Evaluation and Management of Hypoactive Sexual Desire Disorder.
P2860
Q26751514-7BE39CFA-E278-4DB5-B597-E55510CD5F0EQ26861672-4FB1E178-77CF-4724-BF51-CA92AE2248E0Q28552843-A02334AD-BCE5-48FA-AA89-44996AAB4B65Q30276805-0BC15B3D-CE33-4C26-A55B-8E42BF80AA81Q30278438-4712F28B-A5F4-490A-91AF-D754AAD06545Q33166265-41094CAC-ACC1-4B79-A6EF-BC2AAB074124Q33166596-8AC7E0F3-B9BE-4B2D-AC34-3F85E7139C8FQ33166719-8FED59BA-4691-46B1-B753-CE15523D9C0FQ34043125-2E01F21F-0006-449F-B8AE-3F24B6320C66Q34336933-DC7B15F8-50DF-4860-9113-41749D19BE8EQ34465301-0A5B284A-D240-4A48-AF0C-67A1236F80DAQ36216746-DD624B5A-790B-48FD-B0E9-D2D9F144EF0DQ36655856-4CEED93C-4CD5-465F-9EC2-FC5D603E3A6DQ36730209-D8AC1F6C-1017-41BD-BB07-9BA3636EF940Q36810368-34E0AE9A-2669-4922-82F6-F9C50FCEC848Q36979907-204AE477-BD2D-4391-BEF5-2442CB600475Q37711908-1834BB2B-BBFB-46E6-9B26-A3BF3FF8BAB3Q38044019-06077388-FB7E-452B-BECD-6514F57A57A7Q38594117-99E24960-C3AC-44FD-86BC-B69070C40B63Q38731869-E433FB94-04CC-48DE-BD58-40F586543743Q38744650-E9F3B36E-4A52-424E-8282-7613CB19FBB8Q38746601-6B0E506F-1527-4761-ACE6-AF21CC15EF63Q38824509-7E3A09BC-18DE-458D-97B0-2E841FBA1856Q39011718-6BA38F56-6100-4494-B0EC-B47CA9AC55F5Q39262633-19A30072-38B9-4F47-89E9-7E36D4FB4C64Q42688204-EF48A937-262D-4CDB-9629-4C93C8891156Q45065520-296C7B83-85AF-4872-9739-98401A39792BQ46204748-4B8B1EB8-E281-482A-AB35-32232AB67CB9Q47139841-68C0B524-E88C-4D8B-B595-1BEA1A096DFAQ47868863-B613FCD1-3961-4644-AAA8-90855D413458Q48073779-E0899D1A-7AE9-4383-B3F1-A324BA7140B1Q48094293-7D7107FA-66A7-4AD0-AAA1-58F9A8DD415FQ53437731-6328F548-B8CB-472A-858F-19EC06A472D4
P2860
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@ast
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@en
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@nl
type
label
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@ast
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@en
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@nl
prefLabel
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@ast
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@en
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@nl
P2093
P1476
Treatment of hypoactive sexual ...... libanserin in the DAISY study.
@en
P2093
DAISY trial investigators
Dan Dattani
James Simon
John Thorp
Leslie Taylor
Lynna Lesko
Miguel Garcia
Robert Pyke
Toshio Kimura
P304
P356
10.1111/J.1743-6109.2011.02595.X
P577
2012-01-12T00:00:00Z